ENHERTU AstraZeneca Pty Ltd
Product name
ENHERTU
Sponsor
Accepted date
Apr-2026
Active ingredients
trastuzumab deruxtecan
Summary of proposed indication
ENHERTU (trastuzumab deruxtecan) in combination with pertuzumab is indicated for the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.
Application type
C (new indication)
Publication date
Apr-2026